These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Multiple myeloma and acute leukemia associated with alkylating agents. Kyle RA; Pierre RV; Bayrd ED Arch Intern Med; 1975 Jan; 135(1):185-92. PubMed ID: 1053891 [TBL] [Abstract][Full Text] [Related]
4. Acute leukemia after chemotherapy (melphalan). Einhorn N Cancer; 1978 Feb; 41(2):444-7. PubMed ID: 272946 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer and acute leukemia in a patient with multiple myeloma treated with melphalan. Meytes D; Katz DR Isr J Med Sci; 1973 Aug; 9(8):1044-7. PubMed ID: 4753846 [No Abstract] [Full Text] [Related]
8. Three cases of multiple myeloma developing into melphalan-related chronic myelomonocytic leukemia. Ueki K; Sato S; Tamura J; Sawamura M; Murakami H; Naruse T; Tsuchiya J J Med; 1991; 22(3):157-61. PubMed ID: 1770323 [TBL] [Abstract][Full Text] [Related]
9. Melphalan in multiple myeloma. Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709 [No Abstract] [Full Text] [Related]
10. Alkylating agents as leukemogens in multiple myeloma. Karchmer RK; Amare M; Larsen WE; Mallouk AG; Caldwell GG Cancer; 1974 Apr; 33(4):1103-7. PubMed ID: 4522494 [No Abstract] [Full Text] [Related]
11. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol; 2000 Aug; 65(2):123-7. PubMed ID: 10966173 [TBL] [Abstract][Full Text] [Related]
12. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents. Ringborg U; Lewensohn R Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439 [TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma and acute leukemia. Simultaneous evolution of plasmacyte and myelomonocytic clones]. Renoux M; Bernard JF; Bezeau A; Amar M; Boivin P Sem Hop; 1978 Sep 18-25; 54(25-28):809-13. PubMed ID: 214859 [TBL] [Abstract][Full Text] [Related]
14. [Development of acute leukosis in multiple myeloma after prolonged treatment with melphalan]. Scheinberg MA; Bezerra JB; Silveira LA; Ferreira HC; Maspes V AMB Rev Assoc Med Bras; 1978 Oct; 24(10):356-7. PubMed ID: 311053 [No Abstract] [Full Text] [Related]
15. Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience. Cornwell GG; Pajak TF; McIntyre OR Cancer Treat Rep; 1979 Mar; 63(3):399-403. PubMed ID: 427822 [TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Rosner F; Grünwald H Am J Med; 1974 Dec; 57(6):927-39. PubMed ID: 4611209 [No Abstract] [Full Text] [Related]
17. Erythroleukemia following melphalan therapy for multiple myeloma. Fishman SA; Ritz ND N Y State J Med; 1975 Nov; 75(13):2402-4. PubMed ID: 1059018 [No Abstract] [Full Text] [Related]
18. [Myeloma, melphalan and acute myelo-monocytic leukemia. Apropos of a case]. Cywiner-Golenzer C; Adotti F; Marsan C; Quillard A; Henon P; Grimaldi A; Dryll A Sem Hop; 1974 Jan; 50(3):207-11. PubMed ID: 4367926 [No Abstract] [Full Text] [Related]
19. [Case of IgG-K myeloma successfully treated with melphalan but terminating in acute myelogenous leukemia 2 years and 8 months later]. Saitoh A; Tsushima T; Narita K; Fujiwara S; Kawamura S; Chiba Y; Yoshida Y Rinsho Ketsueki; 1982 Jun; 23(6):862-9. PubMed ID: 6960198 [No Abstract] [Full Text] [Related]